Heparin: Mechanism of Action, Pharmacokinetics, Dosing Considerations, Monitoring, Efficacy, and Safety

This publication has 171 references indexed in Scilit:

• Plasminogen activator italian multicenter study (PAIMS): Comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-pa) with intravenous streptokinase in acute myocardial infarction
  Journal of the American College of Cardiology, 1989
• The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mg
  The Journal of Clinical Pharmacology, 1988
• Activation of heparin cofactor II by heparin oligosaccharides
  Biochemical and Biophysical Research Communications, 1988
• Role of heparin after intravenous thrombolytic therapy for acute myocardial infarction
  The American Journal of Cardiology, 1987
• HEPARIN DOSES AND MAJOR BLEEDINGS
  The Lancet, 1986
• Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity
  Biochemical and Biophysical Research Communications, 1983
• TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS BY NEW HEPARINOID
  The Lancet, 1983
• Highly active heparin species with multiple binding sites for antithrombin
  Biochemical and Biophysical Research Communications, 1979
• Anticoagulant activity of heparin: Separation of high‐activity and low‐activity heparin species by affinity chromatography on immobilized antithrombin
  FEBS Letters, 1976
• EFFICACY OF LOW-DOSE HEPARIN IN PREVENTION OF EXTENSIVE DEEP-VEIN THROMBOSIS IN PATIENTS UNDERGOING TOTAL-HIP REPLACEMENT
  The Lancet, 1976